Enveric Biosciences (ENVB) Accumulated Expenses (2015 - 2026)
Enveric Biosciences (ENVB) posted Accumulated Expenses of $180361.0 for Q1 2026, down 24.06% sequentially from $237505.0 in Q4 2025, and down 56.42% YoY from $413837.0 in Q1 2025.
Enveric Biosciences (ENVB) Accumulated Expenses (2015 - 2026) Analysis & Trends
Enveric Biosciences has reported Accumulated Expenses for 9 years, with the latest figure at $180361.0 in Q1 2026.
- Quarterly Accumulated Expenses fell 56.42% year-over-year to $180361.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $180361.0 (down 56.42% YoY) and the FY2025 annual result came in at $237505.0, down 67.69% from the prior year.
- Accumulated Expenses eased to $180361.0 in Q1 2026 per ENVB's latest filing, from $237505.0 in the prior quarter.
- Over five years, Accumulated Expenses peaked at $1.5 million in Q3 2023 and troughed at $8634.0 in Q2 2024.
- A 5-year average of $629773.0 and a median of $413837.0 in 2025 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2025: Accumulated Expenses slumped 99.43% in 2024, then surged 2480.99% in 2025.
- Over 5 years, Accumulated Expenses stood at $1.2 million in 2022, then decreased by 8.53% to $1.1 million in 2023, then sank by 31.66% to $735098.0 in 2024, then tumbled by 67.69% to $237505.0 in 2025, then decreased by 24.06% to $180361.0 in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $180361.0, $237505.0, and $222178.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 180,361.00 |
| Dec 31, 2025 | 237,505.00 |
| Sep 30, 2025 | 222,178.00 |
| Jun 30, 2025 | 222,843.00 |
| Mar 31, 2025 | 413,837.00 |
| Dec 31, 2024 | 735,098.00 |
| Sep 30, 2024 | 8,736.00 |
| Jun 30, 2024 | 8,634.00 |
| Mar 31, 2024 | 112,708.00 |
| Dec 31, 2023 | 1.08 Mn |
| Sep 30, 2023 | 1.53 Mn |
| Jun 30, 2023 | 1.50 Mn |
| Mar 31, 2023 | 397,912.00 |
| Dec 31, 2022 | 1.18 Mn |
| Sep 30, 2022 | 1.11 Mn |
| Jun 30, 2022 | 1.00 Mn |
| Mar 31, 2022 | 764,022.00 |
| Dec 31, 2021 | 1.29 Mn |
| Dec 31, 2020 | 681,250.00 |
| Sep 30, 2016 | 1.35 Mn |